Streetbeat News

Equity Actions

GRI

GRI Bio, Inc. (NASDAQ:GRI) announced the pricing of a $4M public offering, including Series C-1 and C-2 warrants. If fully exercised, the warrants could bring in an additional $8M. The offering is expected to close around June 28, 2024, with H.C. Wainwright & Co. as the exclusive placement agent.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 12:20 pm

NYCB

New York Community Bancorp (NYSE: NYCB) has announced a 1-for-3 reverse stock split, expected to become effective in mid-to-late July. This decision was approved by shareholders at the annual meeting on June 5th.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 12:15 pm

HUBC

Hub Security has restructured $8M of its debt due this month and secured an additional $2M in debt financing. Key shareholders exercised warrants at $0.90 per share, adding $5M in capital.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 12:13 pm

DARE

Daré Bioscience (NASDAQ:DARE) announced a 1-for-12 reverse stock split effective July 1, 2024. The stock will trade on a split-adjusted basis starting that day under the same symbol, DARE.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 12:12 pm

TRML

Tourmaline Bio has appointed Ryan Robinson as the new Chief Financial Officer, effective June 25.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 12:06 pm

IPA

ImmunoPrecise Antibodies has appointed Kristin Taylor as the Chief Financial Officer, transitioning her from the interim CFO role to a permanent position effective immediately.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 12:05 pm

KALA

KALA BIO has announced a $12.5 million private placement.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 12:01 pm

BOF

Branchout Food shares are trading lower following the announcement of a $1.4 million underwritten public offering of 1.75 million shares at $0.80 per share.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 11:50 am

SGHC

Super Group has announced the initiation of a dividend program, declaring its first cash dividend of $0.10 per share, payable on July 17, 2024. The company plans to pay regular dividends annually and intends to switch to quarterly payments starting in the first quarter of 2025, subject to Board approval.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 11:35 am

RXRX

Recursion Pharmaceuticals shares are trading lower after the company announced the pricing of a $200 million public offering of 30,769,230 shares at $6.50 per share.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 11:34 am